Baricitinib is a selective JAK1 and JAK2 inhibitor. IC50 values are 5.9nm for JAK1, and 5.7nM for JAK2. In cell based assays Baricitinib/INCB-28050 demonstrated inhibition of intracellular signaling of multiple pro-inflammatory cytokines including IL-6 and IL-23 at concentrations of < 50 nM, and also showed good efficacy in a number of animal models at doses of 10mg/kg and below. Baricitinib is in Phase III development as a potential treatment for rheumatoid arthritis. It is in Phase II development as a potential treatment for psoriasis and diabetic nephropathy.
Product Details
| Alternative Name: | INCB028050, LY3009104, 2-[1-Ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile |
| |
| Formula: | C16H17N7O2S . H3PO4 |
| |
| MW: | 469.4 |
| |
| CAS: | 1187595-84-1 |
| |
| Purity: | ≥99% (HPLC) |
| |
| Identity: | Determined by EM-MS, NMR |
| |
| Appearance: | White powder. |
| |
| Solubility: | Soluble in DMSO (74mg/ml) or ethanol (1mg/ml). |
| |
| Shipping: | Ambient Temperature |
| |
| Short Term Storage: | +4°C |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
